stockrowWaters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.
- Revenue
- +120.9%
- EPS
- −67.0%
- Free cash flow
- −66.7%
- Total debt
- +308.2%
Quarter to September 2026, against a year earlier
Follow WAT
Alert me
Waters Corporation 10-Q filed Nov 4, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2025: 7 added · 1 removed · 38 modified; 10 with only figures updated; 1 moved without change
-
Modified · Acquisition of BD Biosciences & Diagnostic Solutions Businesses
Prior to, and as a condition of, the Distribution, SpinCo will make a cash payment to BD equal to $4.0 billion (the “SpinCo Cash Distribution”), subject to adjustment for cash, working capital and indebtedness of SpinCo and subject to decrease if additional shares of Company Common Stock will be issued to the Company’s shareholders. The SpinCo Cash Distribution is expected to be paid using proceeds from approximately $4.0 billion of new indebtedness to be incurred by SpinCo prior to the Distribution. The Company is expected to assume all indebtedness incurred by SpinCo in connection with the payment of the SpinCo Cash Distribution upon completion of the Merger. Based on information available through the date of this
filingreport, if the transaction closes, the Company estimates it will incur transaction-related expenses and financing fees of approximately $120140 million in total.